Board of Directors
The GI Dynamics board is committed to carrying out our mission of improving the lives of people suffering from the global epidemics of type 2 diabetes and obesity through the development and commercialization of breakthrough treatments.
Daniel J. Moore (Chairman)
In addition to serving as Chairman of the GI Dynamics board, Dan is also the President and CEO of the Cyberonics medical device company.
Dr. Oern Stuge
Dr. Oern Stuge, MD, MBA, brings significant experience in medical devices and specifically in type 2 diabetes and obesity. He has also lead successful clinical development programs and global commercialization efforts and has held executive and board positions with numerous medical device companies over the past 30 years. As director, he has helped lead several successful company exits, raised significant capital and launched an IPO.
Anne J. Keating
In addition to her role at GI Dynamics, Anne is also a director at REVA Medical, the Garvan Institute of Medical Research, Ardent Leisure Management, and the Goodman Group.
Timothy J. Barberich
In addition to GI Dynamics, Tim also serves on the boards of Heartware International, Inc., Tokai Pharmaceuticals, Euthymics Neuroscience, and Newcastle Holdings. He is a chairman of BioNevia Pharmaceuticals, and is the founder and former CEO of Sepracor, Inc.
Graham J. Bradley
Graham serves as a chairman for Stockland Corporation Limited, Energy Australia Holdings Limited, HSBC Australia Ltd., and Virgin Australia International Ltd., in addition to acting on the GI Dynamics board.
Juliet Thompson has advised and raised capital for healthcare companies for more than 20 years and founded Code Securities, a healthcare investment banking firm that was sold to Nomura. In addition to GI Dyanmics, Juliet also serves as NED for Nexstim Limited, NED for Novacyt SA, and is the chair of Premier Veterinary Group Plc.